Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.57 |
| ▸ | CRHBP | P24387 | 3/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116074 | 1.00 | NAMPT (0.57) | NAMPTCRHBPCRHR2KMT2AALDH1A1 | |
| SCHEMBL10116076 | 0.89 | HSD17B10 (0.51) | NAMPTKMT2ANPC1LMNAATM | |
| SCHEMBL10134197 | 0.89 | HSD17B10 (0.51) | NAMPTKMT2ANPC1LMNAATM | |
| SCHEMBL10115911 | 0.87 | MAPT (0.48) | NAMPTKMT2AALDH1A1NPC1LMNA | |
| SCHEMBL10115860 | 0.87 | MAPT (0.48) | NAMPTKMT2AALDH1A1NPC1LMNA | |
| SCHEMBL12882027 | 0.86 | NAMPT (0.57) | NAMPTCRHBPCRHR2KMT2AALDH1A1 | |
| SCHEMBL10133501 | 0.86 | NAMPT (0.49) | NAMPTCRHBPCRHR2KMT2AALDH1A1 | |
| SCHEMBL10115730 | 0.86 | NAMPT (0.57) | NAMPTCRHBPCRHR2KMT2AALDH1A1 | |
| SCHEMBL10114882 | 0.86 | NAMPT (0.49) | NAMPTCRHBPCRHR2KMT2AALDH1A1 | |
| SCHEMBL14424644 | 0.86 | NAMPT (0.49) | NAMPTCRHBPCRHR2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | NAMPT 2350/4885CRHBP 256/4885CRHR2 13/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | NAMPT 2832/4885CRHBP 247/4885CRHR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.